



Systemic Lupus Erythematosus: From Molecular Mechanisms to Therapies

Guest Editor:

Prof. Dr. Mikhail Kostik

Department of Hospital
Pediatrics, Saint Petersburg State
Pediatric Medical University,
Ministry of Health of Russia 2,
Litovskaya St., Saint Petersburg
194100, Russia

Deadline for manuscript
submissions:

closed (31 December 2023)

Message from the Guest Editor

Systemic lupus erythematosus is a second after rheumatoid arthritis systemic rheumatic disease, with different organ and system involvement with different courses. Systemic lupus erythematosus may affect all ages. Monogenic SLE should be mentioned in early-onset and family cases. The interferon-I signaling pathway and other inherited immune-mediated disturbances are the basis of SLE pathogenesis. The study of molecular and immunology mechanisms is the key to finding new surrogate biomarkers of activity and new targeting treatment options. The research of SLE pathogenesis can improve the patients' quality of life, live expectancy and long-term outcomes. This Special Issue of *Biomedicines* focuses on recent advances in the discovery, characterization, translation, and clinical application of systemic lupus erythematosus and targets. Our goal in publishing this Issue is to stimulate research and clinical interests in this exciting field, with the hope of developing strategies for the diagnosis and assessment of activity and damage, molecular pathogenesis, and improvement of treatment outcomes for patients with systemic lupus erythematosus.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPLus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
X@Biomed_MDPI